MedTrace Logo

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

NCT06998771 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2025-05-31

No results posted yet for this study

Summary

This study is designed to evaluate the safety and efficacy of JSKN003 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer or resectable gastric cancer.

Conditions

  • HER2-positive Gastric Cancer

Interventions

DRUG

JSKN003

JSKN003 is administered by intravenous infusion.

DRUG

KN026

KN026 is administered by intravenous infusion.

DRUG

Capecitabine

Capecitabine is for oral administration.

DRUG

Enlonstobart

Enlonstobart is administered by intravenous infusion.

DRUG

Oxaliplatin

Oxaliplatin is administered by intravenous infusion.

DRUG

Trastuzumab

Trastuzumab is administered by intravenous infusion.

DRUG

Pembolizumab

Pembolizumab is administered by intravenous infusion.

Sponsors & Collaborators

  • Shanghai JMT-Bio Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-15
Primary Completion
2028-06-30
Completion
2029-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06998771 on ClinicalTrials.gov